← All trials
NCT02280486
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Oct 1, 2016
- Completion date
- Oct 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 380
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Nanjing UniversityLead sponsor
- Huai'an First People's HospitalCollaborator
- Nanjing UniversityOverall official - principal investigator
- Nanjing UniversityReponsible party - principal investigator
- Changzhou No.2 People's HospitalCollaborator
- Southeast UniversityCollaborator
- Wuxi People's HospitalCollaborator
- Soochow UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Anhui College of Traditional Chinese MedicineCollaborator
- People's Liberation Army of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.